Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Debt / NOTE 3.500% 9/1
-
Number of holders
-
12
-
Total 13F principal, excl. options
-
93,849,454
-
Principal change
-
-11,723,342
-
Total reported value, excl. options
-
$118,114,618
-
Value change
-
-$56,841,055
-
Number of buys
-
4
-
Number of sells
-
-9
-
Price
-
$1.26
Significant Holders of APELLIS PHARMACEUTICALS INC - NOTE 3.500% 9/1 as of Q3 2023
17 filings reported holding 03753UAB2 - APELLIS PHARMACEUTICALS INC - NOTE 3.500% 9/1 as of Q3 2023.
APELLIS PHARMACEUTICALS INC - NOTE 3.500% 9/1 has 12 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $93,849,454 of principal
.
Largest 10 bondholders include DeepCurrents Investment Group LLC ($39,528,000 of principal), Linden Advisors LP ($15,000,000 of principal), LAZARD ASSET MANAGEMENT LLC ($12,242,000 of principal), WOLVERINE ASSET MANAGEMENT LLC ($11,766,000 of principal), Voya Investment Management LLC ($6,000,000 of principal), D. E. Shaw & Co., Inc. ($5,000,000 of principal), WELLINGTON MANAGEMENT GROUP LLP ($1,285,000 of principal), JPMORGAN CHASE & CO ($1,195,000 of principal), PALISADE CAPITAL MANAGEMENT, LP ($1,017,000 of principal), and CITIGROUP INC ($504,000 of principal).
This table shows the top 12 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.